Recall Register

Drug recall: Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled…

Class II FDA enforcement event 88100. Recall start date: . Status in the FDA record: Terminated. Termination date: .

Reason for recall, in the words of FDA

Failed Stability Specifications: Out of Specification results of Polysorbate 20 (PS20) content were detected at the 12 month testing time point.

Class II, in the words of FDA

a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote

Genentech Inc started this drug recall on 9 Jun 2021. The firm address in the FDA record is in South San Francisco, CA. FDA put the recall in Class II. FDA event 88100 has 1 product record. The first FDA enforcement report date is 14 Jul 2021. The record gives the status Terminated, with the termination date 11 Aug 2022. 90 of the 299 drug events that started in 2021 have more product records. The median drug event of 2021 has 1 product record. The openFDA file has 299 drug events that started in 2021 and 342 that started in 2020.

It is important to note that most of the time recall classifications are determined after the recalling firm provides all of the information needed to determine the risk posed to public health. The classification and posting in the FDA Enforcement Report should not be seen as an expansion or change to a firm’s voluntary public warning.

FDA publishes these words. Source: FDA, Enforcement Reports, Important Note, read on . openFDA export of .

Distribution

In the words of FDA.

Product was distributed nationwide

Recalling firm

Genentech Inc, South San Francisco, CA.

Recalling firm: The firm that the FDA record names for a recall.

FDA records how the recall started: Voluntary: Firm initiated.

Products

1 product record in the event.

FDA event 88100: product records
Recall numberProductQuantityClassStatusReport date
D-0650-2021Xolair (omalizumab) Injection, 150 mg/1 mL, 1 prefilled syringe, Rx Only, For Subcutaneous Use. Single-Dose Prefilled Syringe. Product of France, Manufactured by: Genentech, Inc. A Member of the Roche Group, South San Francisco, CA 9480-4990. NDC: 50242-215-0188,620 prefilled syringesClass IITerminated14 Jul 2021

openFDA, about the status: FDA does not update the status of a recall after the recall has been classified according to its level of hazard. As such, the status of a recall (open, completed, or terminated) will remain unchanged after published in the Enforcement Reports. Source: openFDA, Drug Recall Enforcement Reports, Disclaimer.

Enforcement report: The FDA publication that lists recalls. It has one record for each product of a recall.

Enforcement event: All the product records that have one FDA event number. This site shows one event on one page.

Class II: The middle of the three FDA recall classes.

The event in context

Drug events that started in 2021
299
Share of these events in Class II
60%
Product records in this event
1Median of the firm: 1
Events of the firm on the register
10

Other events of the firm

Official channels

Cite this page

Recall Register. FDA enforcement event 88100. https://recallregister.com/fda/ii/88100/. Source: openFDA enforcement reports. Data through .

Sources

Source
openFDA drug enforcement reports
Licence
CC0 1.0
Export date
10 Nov 2026
Newest FDA report date on the register
4 Nov 2026

FDA has one record for each product. This site puts the records with the same event number on one page. The class of the event is the highest class of its records. How the register is made. Report an error.

Questions

Where was the product distributed?
The FDA record gives this distribution: Product was distributed nationwide
What quantity of product is in FDA event 88100?
The FDA record gives this quantity: 88,620 prefilled syringes
How did the recall start?
The FDA record says: Voluntary: Firm initiated
How many drug recalls of 2021 have the same class?
60% of the 299 drug events that started in 2021 are in Class II.